title: LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
abstract: Phosphatidylinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) pathway plays a major role in proliferation and survival of many types of cells. The inhibitory effect of LY294002, widely applied as an inhibitor of PI3K, in combination with gemcitabine on proliferation of PANC-1 cells was investigated. The expression of PI3K, phosphorylated Akt (p-Akt) and multidrug-resistance like protein (MRP) in normal pancreas tissues, chronic pancreatitis tissues and pancreatic carcinoma tissues was detected. The effects of LY294002 combined with gemcitabine on proliferation of PANC-1 cells and protein levels of p-Akt and MRP were detected. The results showed that the positive expression rate of PI3K, p-Akt and MRP in pancreatic carcinoma tissues was significantly higher than that in normal pancreas tissues and chronic pancreatitis tissues (P<0.01 and P<0.05 respectively). LY294002 could effectively enhance the inhibitory effect of gemcitabine on proliferation of PANC-1 cells. Furthermore, Western blotting revealed that LY294002 combined with gemcitabine reduced the protein levels of p-Akt and MRP, which contributed to the inhibition of proliferation. It is concluded that LY294002 in combination with gemcitabine may represent an alternative therapy for pancreatic carcinoma.
authors: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. jessicawarm@hotmail.com.|Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. jessicawarm@hotmail.com.
authors: Xiao-Yu
authors: XY
authors: Ke
authors: Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors: Yu
authors: Y
authors: Wang
authors: Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors: Zuo-Qi
authors: ZQ
authors: Xie
authors: Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors: Zhi-Qing
authors: ZQ
authors: Liu
authors: Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors: Cui-Fang
authors: CF
authors: Zhang
authors: Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. tongji461@sina.com.
authors: Qiu
authors: Q
authors: Zhao
authors: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
authors: Dong-Liang
authors: DL
authors: Yang
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D049109:Cell Proliferation / Q000187:drug effects; D002867:Chromones / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000379:methods; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D002867:Chromones; D004791:Enzyme Inhibitors; D009025:Morpholines; D000081082:Phosphoinositide-3 Kinase Inhibitors; D003841:Deoxycytidine; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D000093542:Gemcitabine
references: Ann Oncol. 2006 May;17 Suppl 5:v148-52
references: 16807445
references: Cancer Res. 2010 Mar 15;70(6):2146-57
references: 20179189
references: J Surg Res. 2010 May 1;160(1):90-101
references: 19560785
references: J Gastrointest Surg. 2003 Mar-Apr;7(3):354-63
references: 12654560
references: J Huazhong Univ Sci Technolog Med Sci. 2010 Jun;30(3):360-4
references: 20556582
references: Gut. 2005 Jan;54(1):109-16
references: 15591514
references: Cancer Res. 2007 Jun 15;67(12):5779-88
references: 17575145
references: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references: 20180029
references: Cancer Res. 2004 Nov 15;64(22):8397-404
references: 15548710
references: Anticancer Res. 2007 Jul-Aug;27(4B):2115-20
references: 17695494
references: J Gastrointest Surg. 2008 Feb;12(2):288-96
references: 18049840
references: Mol Cancer Ther. 2002 Oct;1(12):989-97
references: 12481421
references: Clin Cancer Res. 2010 Oct 15;16(20):4928-37
references: 20876794
references: Br J Cancer. 2003 Jun 16;88(12):1963-70
references: 12799644
references: Cancer Res. 2007 May 1;67(9):4149-56
references: 17483325
references: Br Med Bull. 2008;87:97-130
references: 18753179
references: Cancer Res. 2005 Feb 15;65(4):1497-504
references: 15735038
references: Jpn J Clin Oncol. 2004 May;34(5):238-44
references: 15231857
references: Cancer Res. 2000 Oct 1;60(19):5451-5
references: 11034087
references: Int J Cancer. 2009 Aug 15;125(4):942-51
references: 19405118
references: Cancer Sci. 2008 Sep;99(9):1734-40
references: 18616528
references: Med Oncol. 2010 Sep;27(3):1017-22
references: 19816816
references: Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):327-48
references: 16549331
references: Mol Cancer Ther. 2006 Apr;5(4):787-96
references: 16648548
references: Pancreas. 2004 Apr;28(3):353-8
references: 15084985